Using an altered version of the smallpox vaccine to deliver a hefty dose of the drug into a cancer cell, tiny Jennerex has vaulted to a lead position in the busy field of oncolytic viruses. In the space of a few months, the San Francisco company has shown that its drug, JX-594, is replicating inside cancer cells and that a protein slipped into the drug sets off an immune system response to those cells.
What’s more, the company said this month, a mid-stage trial showed that high doses of JX-594 more than doubled life expectancy for liver cancer patients, compared with patients given a low dose of the drug.
No comments:
Post a Comment